Calcitriol in cancer treatment: From the lab to the clinic

Tomasz (Tom) Beer, Anne Myrthue

    Research output: Contribution to journalArticle

    131 Citations (Scopus)

    Abstract

    1,25-Dihydroxyvitamin D (calcitriol), the most active metabolite of vitamin D, has significant antineoplastic activity in preclinical models. Several mechanisms of activity have been proposed. These include inhibition of proliferation associated with cell cycle arrest and, in some models, differentiation, reduction in invasiveness and angiogenesis, and induction of apoptosis. Proposed mechanisms differ between tumor models and experimental conditions, and no unifying hypothesis about the mechanism of antineoplastic activity has emerged. Synergistic and/or additive effects with cytotoxic chemotherapy, radiation, and other cancer drugs have been reported. Significantly supraphysiological concentrations of calcitriol are required for antineoplastic effects. Such concentrations are not achievable in patients when calcitriol is dosed daily due to predictable hypercalcemia and hypercalcuria; however, phase I trials have demonstrated that intermittent dosing allows substantial dose escalation and has produced potentially therapeutic peak calcitriol concentrations. Recently, a phase II study reported encouraging levels of activity for the combination of high-dose calcitriol and docetaxel administered on a weekly schedule in patients with androgen-independent prostate cancer. This regimen is now under study in a placebo-controlled randomized trial in androgen-independent prostate cancer and in phase II studies in several other tumor types. Further work is needed to elucidate the molecular mechanisms of antineoplastic activity and optimal clinical applications of calcitriol in cancer.

    Original languageEnglish (US)
    Pages (from-to)373-381
    Number of pages9
    JournalMolecular Cancer Therapeutics
    Volume3
    Issue number3
    StatePublished - Mar 2004

    Fingerprint

    Calcitriol
    Antineoplastic Agents
    Neoplasms
    docetaxel
    Androgens
    Prostatic Neoplasms
    Therapeutics
    Hypercalcemia
    Cell Cycle Checkpoints
    Vitamin D
    Appointments and Schedules
    Theoretical Models
    Randomized Controlled Trials
    Placebos
    Radiation
    Apoptosis
    Drug Therapy
    Pharmaceutical Preparations

    ASJC Scopus subject areas

    • Oncology
    • Drug Discovery
    • Pharmacology

    Cite this

    Calcitriol in cancer treatment : From the lab to the clinic. / Beer, Tomasz (Tom); Myrthue, Anne.

    In: Molecular Cancer Therapeutics, Vol. 3, No. 3, 03.2004, p. 373-381.

    Research output: Contribution to journalArticle

    @article{21456abbb8e441c383810723bb423205,
    title = "Calcitriol in cancer treatment: From the lab to the clinic",
    abstract = "1,25-Dihydroxyvitamin D (calcitriol), the most active metabolite of vitamin D, has significant antineoplastic activity in preclinical models. Several mechanisms of activity have been proposed. These include inhibition of proliferation associated with cell cycle arrest and, in some models, differentiation, reduction in invasiveness and angiogenesis, and induction of apoptosis. Proposed mechanisms differ between tumor models and experimental conditions, and no unifying hypothesis about the mechanism of antineoplastic activity has emerged. Synergistic and/or additive effects with cytotoxic chemotherapy, radiation, and other cancer drugs have been reported. Significantly supraphysiological concentrations of calcitriol are required for antineoplastic effects. Such concentrations are not achievable in patients when calcitriol is dosed daily due to predictable hypercalcemia and hypercalcuria; however, phase I trials have demonstrated that intermittent dosing allows substantial dose escalation and has produced potentially therapeutic peak calcitriol concentrations. Recently, a phase II study reported encouraging levels of activity for the combination of high-dose calcitriol and docetaxel administered on a weekly schedule in patients with androgen-independent prostate cancer. This regimen is now under study in a placebo-controlled randomized trial in androgen-independent prostate cancer and in phase II studies in several other tumor types. Further work is needed to elucidate the molecular mechanisms of antineoplastic activity and optimal clinical applications of calcitriol in cancer.",
    author = "Beer, {Tomasz (Tom)} and Anne Myrthue",
    year = "2004",
    month = "3",
    language = "English (US)",
    volume = "3",
    pages = "373--381",
    journal = "Molecular Cancer Therapeutics",
    issn = "1535-7163",
    publisher = "American Association for Cancer Research Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Calcitriol in cancer treatment

    T2 - From the lab to the clinic

    AU - Beer, Tomasz (Tom)

    AU - Myrthue, Anne

    PY - 2004/3

    Y1 - 2004/3

    N2 - 1,25-Dihydroxyvitamin D (calcitriol), the most active metabolite of vitamin D, has significant antineoplastic activity in preclinical models. Several mechanisms of activity have been proposed. These include inhibition of proliferation associated with cell cycle arrest and, in some models, differentiation, reduction in invasiveness and angiogenesis, and induction of apoptosis. Proposed mechanisms differ between tumor models and experimental conditions, and no unifying hypothesis about the mechanism of antineoplastic activity has emerged. Synergistic and/or additive effects with cytotoxic chemotherapy, radiation, and other cancer drugs have been reported. Significantly supraphysiological concentrations of calcitriol are required for antineoplastic effects. Such concentrations are not achievable in patients when calcitriol is dosed daily due to predictable hypercalcemia and hypercalcuria; however, phase I trials have demonstrated that intermittent dosing allows substantial dose escalation and has produced potentially therapeutic peak calcitriol concentrations. Recently, a phase II study reported encouraging levels of activity for the combination of high-dose calcitriol and docetaxel administered on a weekly schedule in patients with androgen-independent prostate cancer. This regimen is now under study in a placebo-controlled randomized trial in androgen-independent prostate cancer and in phase II studies in several other tumor types. Further work is needed to elucidate the molecular mechanisms of antineoplastic activity and optimal clinical applications of calcitriol in cancer.

    AB - 1,25-Dihydroxyvitamin D (calcitriol), the most active metabolite of vitamin D, has significant antineoplastic activity in preclinical models. Several mechanisms of activity have been proposed. These include inhibition of proliferation associated with cell cycle arrest and, in some models, differentiation, reduction in invasiveness and angiogenesis, and induction of apoptosis. Proposed mechanisms differ between tumor models and experimental conditions, and no unifying hypothesis about the mechanism of antineoplastic activity has emerged. Synergistic and/or additive effects with cytotoxic chemotherapy, radiation, and other cancer drugs have been reported. Significantly supraphysiological concentrations of calcitriol are required for antineoplastic effects. Such concentrations are not achievable in patients when calcitriol is dosed daily due to predictable hypercalcemia and hypercalcuria; however, phase I trials have demonstrated that intermittent dosing allows substantial dose escalation and has produced potentially therapeutic peak calcitriol concentrations. Recently, a phase II study reported encouraging levels of activity for the combination of high-dose calcitriol and docetaxel administered on a weekly schedule in patients with androgen-independent prostate cancer. This regimen is now under study in a placebo-controlled randomized trial in androgen-independent prostate cancer and in phase II studies in several other tumor types. Further work is needed to elucidate the molecular mechanisms of antineoplastic activity and optimal clinical applications of calcitriol in cancer.

    UR - http://www.scopus.com/inward/record.url?scp=4444282905&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=4444282905&partnerID=8YFLogxK

    M3 - Article

    C2 - 15026558

    AN - SCOPUS:4444282905

    VL - 3

    SP - 373

    EP - 381

    JO - Molecular Cancer Therapeutics

    JF - Molecular Cancer Therapeutics

    SN - 1535-7163

    IS - 3

    ER -